0001683168-22-007279.txt : 20221104 0001683168-22-007279.hdr.sgml : 20221104 20221104161625 ACCESSION NUMBER: 0001683168-22-007279 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20221104 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221104 DATE AS OF CHANGE: 20221104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Odyssey Health, Inc. CENTRAL INDEX KEY: 0001626644 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 471022125 STATE OF INCORPORATION: NV FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-56196 FILM NUMBER: 221362544 BUSINESS ADDRESS: STREET 1: 2300 WEST SAHARA AVENUE STREET 2: SUITE 800-#4012 CITY: LAS VEGAS STATE: NV ZIP: 89102 BUSINESS PHONE: 702-780-6559 MAIL ADDRESS: STREET 1: 2300 WEST SAHARA AVENUE STREET 2: SUITE 800-#4012 CITY: LAS VEGAS STATE: NV ZIP: 89102 FORMER COMPANY: FORMER CONFORMED NAME: Odyssey Group International, Inc. DATE OF NAME CHANGE: 20141128 8-K 1 odyssey_8k.htm CURRENT REPORT

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2022

ODYSSEY HEALTH, INC.

(Exact name of small business issuer as specified in its charter)

Nevada	000-56196	47-1022125
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer ID No.)

2300 West Sahara Avenue, Suite 800 - #4012, Las Vegas, NV	89102
(Address of principal executive offices)	(Zip Code)

(702) 780-6559

(Issuer’s Telephone Number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
N/A	N/A	N/A

Securities registered pursuant to Section 12(g) of the Act:

Title of each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock ($0.001 par value)	ODYY	OTC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b2 of the Securities Exchange Act of 1934 (§240.12b2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

On November 1, 2022, Odyssey NeuroPharma, Inc. (the “Company”), a wholly-owned subsidiary of Odyssey Health, Inc., a Nevada Corporation ”) entered into employment agreements with Mr. Erik Emerson and Mr. Greg Gironda (the “Executives” “Executives”). See Item 5.02 below for a description of the agreements.

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

Mr. Emerson Employment Agreement

On November 1, 2022, the Company and Mr. Emerson entered into an employment agreement (the “Agreement”) for a one (1) year term as Chief Commercial Officer. The Executive agrees to devote the energies and skills to the discharge of the duties and responsibilities attributable to the position, and to this end will devote 33 and 1/3 percent of business time and attention to the business and affairs of the Company and its affiliated entities. During the employment term, and subject to raising funds, the Company shall pay Mr. Emerson a minimum annual base salary of One Hundred Twenty-Five Thousand Dollars ($125,000) (“Base Salary”). The Base Salary will not begin to be payable until such time that the Company has raised a cumulative of Five Million Dollars ($5,000,000) in funding. Thereafter, the Base Salary will be paid to the Executive. Mr. Emerson will be granted stock options covering Six Hundred Thousand (600,000) shares of our common stock, vesting as follows: One Hundred Twenty-Five Thousand (125,000) vest upon signing of this agreement; Three Hundred Thousand (300,000) vest upon a financing by the Company in the amount of five Million Dollars ($5,000,000) or more; and One Hundred Seventy-Five Thousand (175,000) vest upon the listing of the Company on a national exchange such as Nasdaq or the NYSE. In the event of a Change of Control of the Company, the stock options will become fully vested and exercisable.

Mr. Gironda Employment Agreement

On November 1, 2022, the Company and Mr. Gironda entered into an employment agreement (the “Agreement”) for a one (1) year term as Chief Operations Officer. The Executive agrees to devote the energies and skill to the discharge of the duties and responsibilities attributable to the position, and to this end will devote 33 and 1/3 percent of business time and attention to the business and affairs of the Company and its affiliated entities. During the employment term, and subject to raising funds, the Company shall pay the Mr. Gironda a minimum annual base salary of One Hundred Twenty-Five Thousand Dollars ($125,000) (“Base Salary”). The Base Salary will not begin to be payable until such time that the Company has raised a cumulative of $5,000,000 in funding. Thereafter the Base Salary will be paid to the Executive. Mr. Gironda will be granted stock options covering Six Hundred Thousand (600,000) shares of our common stock, vesting as follows: One Hundred Twenty-Five Thousand (125,000) vest upon signing of this agreement; Three Hundred Thousand (300,000) vest upon a financing by the Company in the amount of five Million Dollars ($5,000,000) or more; and One Hundred Seventy-Five Thousand (175,000) vest upon the listing of the Company on a national exchange such as Nasdaq or the NYSE. In the event of a Change of Control of the Company, the stock options will become fully vested and exercisable.

Mr. Emerson and Mr. Gironda have also agreed to customary restrictions with respect to the disclosure and use of the Company’s confidential information, and have agreed that work product or inventions developed or conceived by them while employed with the Company relating to its business is the Company’s property.

The foregoing description of the employment agreements is a summary and is qualified in its entirety by reference to the employment agreements which are attached hereto as Exhibit 10.1 and Exhibit 10.2 and are incorporated by reference herein.

Item 7.01

Regulation FD Disclosure

Attached is a copy of a press release being issued by the Company relating to the above-referenced matter, a copy of which is attached as Exhibit as 99.1 and is hereby incorporated.

Item 8.01

Other Material Event

On November 3, 2022, Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving medical products, is pleased to announce its continued commitment to the newly formed entity, Odyssey NeuroPharma, with the expansion of its executive team.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.	Description

10.1	Employment Agreement by and between Odyssey Group International, Inc. and Erik Emerson, dated November 1, 2022.
10.2	Employment Agreement by and between Odyssey Group International, Inc. and Greg Gironda, dated November 1, 2022.
99.1	Press Release
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Odyssey Health, Inc.

Date: November 4, 2022	By:	/s/ Joseph Michael Redmond
		Joseph Michael Redmond Chief Executive Officer

EX-10.1 2 odyssey_ex1001.htm EMPLOYMENT AGREEMENT BY AND BETWEEN ODYSSEY GROUP INTERNATIONAL, INC. AND ERIK EMERSON

Exhibit 10.1

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between Odyssey Pharmaceuticals a wholly owned subsidiary of Odyssey Health Inc (the “Company”) a Nevada Corporation and Erik Emerson (the “Executive”) whose address is _________________.

WHEREAS, the Company desires to employ the Executive as its Chief Commercial Officer and the Executive desires to serve in such capacity on behalf of the Company.

WHEREAS, the Company and the Executive desire to enter into this Agreement to set forth the terms and conditions of the employment relationship between the Company and the Executive;

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1. Employment.

(a) Term. Executive’s Term of employment (the “Term”) under this Agreement shall be one (1) year, commencing on November 1, 2022 (the “Effective Date”), and shall continue for a period through and including November 1, 2023 (the “Initial Term”),

(b) Duties. During the Term, the Executive shall serve as the Chief Commercial Officer or other job related to the Company with duties, responsibilities and authority commensurate therewith and shall report to the Chief Executive Officer or his designee (the “CEO”). The Executive shall perform all duties and accept all responsibilities incident to such position as may be reasonably assigned by the CEO. The Executive represents to the Company that he is not subject to or a party to any other employment agreement, non-competition covenant, or other agreement that would be breached by, or prohibit the Executive from executing, this Agreement and performing fully her duties and responsibilities under this Agreement.

(c) Exclusive Services. Subject to the permissions and restrictions specified in Section 14 below, Executive agrees to devote energies and skill to the discharge of the duties and responsibilities attributable to this position, and to this end will devote 33 and 1/3 percent of business time and attention to the business and affairs of the Company and its affiliated entities. The foregoing shall not be construed as preventing the Executive from (1) serving on civic, trade association, industry, educational, philanthropic, charitable or non-profit boards or committees, or, on corporate boards for businesses that are not in competition with the Company, and (2) managing personal investments, so long as such activities do not conflict with the Company’s published code of conduct and employment policies.

(d) Principal Place of Employment. The Executive understands and agrees that the Principal Place of Employment will be in the Executive’s residence and will be required to travel for business in the course of performing the duties for the Company.

2. Compensation.

(a) Base Salary and Accrued compensation. During the Employment Term, and subject to raising funds, the Company shall pay the Executive a minimum annual base salary of $125,000 (“Base Salary”) payable in equal installments at such payment intervals as are the usual custom of the Company, but not less often than monthly. The Base Salary will not begin to be payable until such time that the Company has raised a cumulative of $5,000,000 in funding. Thereafter the Base Salary will be paid to Executive.

(c) Equity Incentive. Executive will be granted stock options per the Odyssey Health Inc. Stock Option Plan in the amount of six hundred thousand (600,000) options The exercise price will be the stock’s closing price on the day the Board of directors approve this agreement and the Stock options. Vesting is as follows:

125,000 vest upon signing of this agreement

300,000 vest upon a financing by the Company in the amount of $5,000,000 or more.

175,000 vest upon the listing of the Company on a national exchange such as Nasdaq or the NYSE.

In the event of a Change of Control (as defined in this Section 2(c)) of the Company while you continue to be employed by the Company, stock options will become fully vested and exercisable. For purposes of this Agreement, a “Change of Control” means that any of the following events has occurred:

(i) Any person or entity (as such term is used in Section 13(d) of the Securities Exchange Act of 1934 (the “Exchange Act”)), other than the Company, any employee benefit plan of the Company or any entity organized, appointed or established by the Company for or pursuant to the terms of any such plan, together with all “affiliates” and “associates” (as such terms are defined in Rule 12b-2 under the Exchange Act) becomes the beneficial owner or owners (as defined in Rule 13d-3 and 13d-5 promulgated under the Exchange Act), directly or indirectly (the “Control Group”), of more than 50% of the outstanding equity securities of the Company, or otherwise becomes entitled, directly or indirectly, to vote more than 50% of the voting power entitled to be cast at elections for directors (“Voting Power”) of the Company;

(ii) A consolidation or merger (in one transaction or a series of related transactions) of the Company pursuant to which the holders of the Company’s equity securities immediately prior to such transaction or series of related transactions would not be the holders, directly or indirectly, immediately after such transaction or series of related transactions of more than 50% of the Voting Power of the entity surviving such transaction or series of related transactions;

(iii) The sale, lease, exchange or other transfer (in one transaction or a series of related transactions) of all or substantially all of the assets of the Company; or

(iv) The liquidation or dissolution of the Company or the Company ceasing to do business.

3. Benefit Plans. During the Employment Term, and as otherwise provided herein, but at the Company’s sole discretion, Executive shall be able to participate in any and all employee welfare and health benefit plans (including, but not limited to, life insurance, health, dental, and disability plans) and other employee benefit plans, including, but not limited to, qualified pension plans, established by the Company from time-to-time for the benefit of all executives of the Company. Executive shall be required to comply with the conditions attendant to coverage by such plans and shall comply with and be entitled to benefits only in accordance with the terms and conditions of such plans as they may be amended from time-to-time. Nothing contained in this Agreement shall be construed as requiring the Company to establish or continue any particular benefit plan in discharge of its obligations under this Agreement or preclude the Company or any affiliate of the Company from terminating or amending any employee benefit plan or program from time-to-time after the Effective Date.

5. Expenses. The Company shall pay or reimburse the Executive for all reasonable, ordinary, and necessary business expenses incurred by the Executive in the performance of the responsibilities and the promotion of the Company’s businesses. All expenses must be pre-approved in writing by the Company. The Executive shall submit to the Company periodic statements of all expenses so incurred. Subject to such reasonable accounting procedures as the Company may adopt generally from time-to-time for executives, the Company shall reimburse the Executive the full amount of any such expenses advanced by him in the ordinary course of business. The Company shall reimburse the Executive for travel to/from the Principal Place of Employment including food and lodging, together with reasonable dues and related expenses for industry associations and groups, publications, required professional training and similar activities. All such expenses must be pre-approved in writing by the Company and reimbursement of expenses shall be paid within fifteen (15) days of submitting receipts for such expenses.

6. Termination .. The Company may terminate the Executive’s employment at any time. Executive may terminate Employment at any time. No severance will be paid to Executive upon termination.

11. Resignation of Positions. Effective as of the date of any termination of employment, the Executive will resign all Company-related positions, including as an officer of the Company and its parents, subsidiaries and affiliates.

13. Section 409A.

(a) This Agreement is intended to comply with Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and its corresponding regulations, or an exemption, and payments may only be made under this Agreement upon an event and in a manner permitted by Code § 409A of the Code, to the extent applicable. Severance benefits under the Agreement are intended to be exempt from Code § 409A under the “short-term deferral” exception, to the maximum extent applicable, and then under the “separation pay” exception, to the maximum extent applicable. Notwithstanding anything in this Agreement to the contrary, if required by Code § 409A, if the Executive is considered a “specified employee” for purposes of Code § 409A and if payment of any amounts under this Agreement is required to be delayed for a period of six months after separation from service pursuant to Code § 409A, payment of such amounts shall be delayed as required by Code § 409A, and the accumulated amounts shall be paid in a lump-sum payment within ten days after the end of the six-month period. If the Executive dies during the postponement period prior to the payment of benefits, the amounts withheld on account of Code § 409A shall be paid to the personal representative of the Executive’s estate within 60 days after the date of the Executive’s death.

(b) All payments to be made upon a termination of employment under this Agreement may only be made upon a “separation from service” under Code § 409A. For purposes of Code § 409A, each payment hereunder shall be treated as a separate payment and the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments. In no event may the Executive, directly or indirectly, designate the calendar year of a payment. Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of the Executive’s execution of the Release, directly or indirectly, result in the Executive designating the calendar year of payment of any amounts of deferred compensation subject to Code § 409A, and if a payment that is subject to execution of the Release could be made in more than one taxable year, payment shall be made in the later taxable year.

(c) All reimbursements and in-kind benefits provided under the Agreement shall be made or provided in accordance with the requirements of Code § 409A, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during the period of time specified in this Agreement, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during a calendar year may not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year, (iii) the reimbursement of an eligible expense will be made no later than the last day of the calendar year following the year in which the expense is incurred, and (iv) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.

14. Restrictive Covenants. Executive acknowledges that her position with the Company is special, unique, and intellectual in character, that in her position she will have special access to and knowledge about Company plans, strategies, intellectual property including trade secrets and know-how, and that her position in the Company will place him in a position of confidence and trust with employees and clients of the Company. For this reason, Executive agrees that the provisions set forth below in this Section 14 are fair and reasonable to the Company, its shareholders, and the Executive.

(a) Non-Solicitation of Company Personnel. During the Term and during the Restriction Period, the Executive hereby agrees that the Executive will not, either directly or through others, hire or attempt to hire any employee, consultant or independent contractor of the Company or its Affiliates, other than an Officer or Director of the Company, or solicit or attempt to solicit any such person to change or terminate her relationship with the Company or an Affiliate or otherwise to become an employee, consultant or independent contractor to, for or of any other person or business entity, unless more than two (2) months shall have elapsed between the last day of such person’s employment or service with the Company or Affiliate and the first date of such solicitation or hiring or attempt to solicit or hire. The provisions of this subsection (b) shall not apply to general employment advertisements, job fairs and other general public solicitations seeking to hire personnel.

(b) Non-Solicitation of Customers. During the Term and during the Restriction Period, the Executive hereby agrees that the Executive will not, either directly or through others, solicit, divert or appropriate, or attempt to solicit, divert or appropriate any customer or prospective customer for which the Company has prepared written proposals for the purpose of providing such customer or prospective customer with services or products directly competitive with those offered by the Company or an Affiliate during the Term.

(c) Proprietary Information. Executive acknowledges that Executive will have access to certain proprietary and confidential information of the Company and its customers and vendors (collectively “Proprietary Information”). At all times, during the Term of this Agreement, the Executive will hold in strictest confidence and will not disclose, use, lecture upon or publish any of the Proprietary Information (defined below) of the Company or an Affiliate, except as such disclosure, use or publication may be required in connection with the Executive’s work for the Company in accordance with this Agreement or as described in Section 14(e) below, or unless the Company expressly authorizes such disclosure in writing. “Proprietary Information” shall mean any and all confidential and/or proprietary knowledge, data or information of the Company and its Affiliates and shareholders, including but not limited to written information relating to financial matters, investments, budgets, business plans, sales projections, cost, pricing and pricing models, marketing and advertising plans, creative campaigns and themes, personnel matters, business contacts, products and contemplated new products and services, processes, know-how, designs, methods, improvements, discoveries, inventions, ideas, data, programs, and other works of authorship that are in writing and marked “Confidential”.

(d) Reports to Government Entities. Nothing in this Agreement shall prohibit or restrict the Executive from initiating communications directly with, responding to any inquiries from, providing testimony before, providing confidential information to, reporting possible violations of law or regulation to, or from filing a claim or assisting with an investigation directly with a self-regulatory authority or a government agency or entity, including the U.S. Equal Employment Opportunity Commission, the Federal Drug Administration, the Department of Labor, the National Labor Relations Board, the Department of Justice, the Securities and Exchange Commission, the United States Congress, and any agency Inspector General (collectively, the “Regulators”), or from making other disclosures that are protected under the whistleblower provisions of state or federal law or regulation. The Executive does not need the prior authorization of the Company to engage in such communications, respond to such inquiries, provide confidential information or documents to the Regulators, or make any such reports or disclosures to the Regulators. The Executive is not required to notify the Company that the Executive has engaged in such communications with the Regulators. If the Executive is required by law to disclose Proprietary Information, other than to Regulators as described above, the Executive shall give prompt written notice to the Company so as to permit the Company to protect its interests in confidentiality to the extent possible.

(f) Invention Assignment. The Executive agrees that all inventions, innovations, improvements, developments, methods, designs, analyses, reports, and all similar or related information which relates to the Company’s or its Affiliates’ actual or anticipated business, research and development or existing or future products or services and which are conceived, developed, created, or made by Executive, alone or with others, whether or not patentable, registerable, or copyrightable, while employed by the Company (“Work Product”) belong to the Company. The Executive will promptly disclose such Work Product to the Board and perform all actions reasonably requested by the Board (whether during or after the Term) to establish and confirm such ownership (including, without limitation, assignments, consents, powers of attorneys, applications for and procuring patents, trademarks, service marks, or copyrights, and other instruments as the Company, in its sole discretion, may request). Executive agrees to give the Company all assistance it may reasonably require, including the giving of testimony in any suit, action, investigation, or other proceeding, to obtain, maintain, and protect the Company’s rights in the Work Product. Executive agrees as a condition of employment to sign and be bound by the Company’s standard Inventions Assignment Agreement. The parties agree that the inventions listed in Exhibit A to this Agreement, which is incorporated in and made a substantive part of this Agreement, are excluded from the application of this subsection (f).

(g) Return of Company Property. All records, files, lists, including computer generated lists, drawings, documents, equipment, and similar items relating to the Company’s business that Executive shall prepare or receive from the Company shall remain the Company’s sole and exclusive property. Upon termination of the Executive’s employment with the Company for any reason, voluntarily or involuntarily, and at any earlier time the Company requests, the Executive will deliver to the person designated by the Company all originals and copies of all documents and property of the Company or an Affiliate that is in the Executive’s possession, under the Executive’s control or to which the Executive may have access. The Executive shall keep one copy of all items related to the Company’s business listed above in this paragraph.

(h) The foregoing provisions of subsections (a), (b), (c), and (d) shall not apply to the company or companies listed in Exhibit B, as may amended from time-to-time by signed written agreement of the Board and Executive, which exhibit is incorporated in and made a substantive part of this Agreement.

(i) Notwithstanding anything in this Agreement to the contrary, and in addition to any other lawful rights and remedies available to the Company, if the Executive breaches any of the Executive’s obligations under Section 14, the Company shall be obligated to provide only the compensation and accrued benefits required by any Company benefit plans, policies or practices then applicable to the Executive in accordance with the terms thereof. In such event, the Company may require that the Executive repay all amounts theretofore paid to him pursuant to Section 6 hereof; and in such case, the Executive shall promptly repay such amounts on the terms determined by the Company up to a maximum of fifty thousand dollars ($50,000.00).

(j) The provisions of this Section 14 and Section 15 below shall survive any termination of the Executive’s employment or the termination or expiration of this Agreement for a period of six months.

15. Legal and Equitable Remedies.

(a) Because the Executive’s services are personal and unique and the Executive has had and will continue to have access to and has become and will continue to become acquainted with the proprietary information of the Company and its Affiliates, and because any breach by the Executive of any of the restrictive covenants contained in Section 14 would result in irreparable injury and damage for which money damages would not provide an adequate remedy, the Executive agrees that Company shall have the right to enforce Section 14 and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that the Company may have for a breach, or threatened breach, of the restrictive covenants set forth in Section 14. The Executive expressly consents to enforcement of Section 14 by means of temporary or permanent injunction and other appropriate equitable relief in any competent court or arbitration tribunal, and agrees that in any action in which the Company seeks injunction, specific performance or other equitable relief, the Executive will not assert or contend that any of the provisions of Section 14 are unreasonable or otherwise unenforceable.

(b) Any and all disputes arising under or relating to the interpretation or application of this Agreement or concerning Executive’s employment with the Company or termination of employment shall be subject to final and binding arbitration in the Chicago, Illinois under the then existing rules of the American Arbitration Association relating to employment matters. Judgment upon the award rendered may be entered in any court of competent jurisdiction. The cost of arbitration and Executive’s legal expenses shall be borne by the Company. Nothing contained in this subsection (b) shall limit the right of the Company to enforce by court injunction or other equitable relief the Executive’s obligations under Section 14. In any court proceeding arising out of this Agreement, the parties (1) irrevocably consent to the exclusive jurisdiction of the United States District Court for Northern District of Illinois or if such court does not have jurisdiction or will not accept jurisdiction, to any court of general jurisdiction in Illinois and (2) waive any objection to the laying of venue of any such proceeding in any such court.

(c) Indemnification. In addition to any rights Executive may have under the Company's charter or by-laws, the Company agrees to indemnify Executive and hold Executive harmless, both during the Term and after the Term or Termination for any reason, of this Agreement, against all costs, expenses (including, without limitation, fines, taxes and attorneys' and accountants’ fees) and liabilities (collectively, "Losses") reasonably incurred by Executive in connection with any claim, action, proceeding or investigation brought against or involving Executive with respect to, arising out of or in any way relating to Executive's employment with the Company or Executive's service as a director of the Company. Executive shall promptly notify the Company of any claim, action, proceeding or investigation under this paragraph and the Company shall be entitled to participate in the defense of any such claim, action, proceeding or investigation and, if it so chooses, to assume the defense with counsel selected by the Company; provided that Executive shall have the right to employ counsel to represent him (at the Company's expense) if Company counsel would have a "conflict of interest" in representing both the Company and Executive. The Company shall not settle or compromise any claim, action, proceeding or investigation without Executive's consent, which consent shall not be unreasonably withheld; provided, however, that such consent shall not be required if the settlement entails only the payment of money and the Company fully indemnifies Executive in connection therewith. The Company further agrees to advance any and all expenses (including, without limitation, the fees and expenses of counsel) reasonably incurred by the Executive in connection with any such claim, action, proceeding or investigation. The Company, as soon as reasonably possible, will maintains a policy of directors' and officers' liability insurance covering Executive and, notwithstanding the expiration or earlier termination of this Agreement, the Company shall maintain a directors' and officers' liability insurance policy covering Executive for a period of time following such expiration or earlier termination equal to the statute of limitations for any claim that may be asserted against Executive for which coverage is available under such directors' and officers' liability insurance policy. All provisions of this paragraph shall survive the termination of this Agreement for any reason.

16. Survival. The respective rights and obligations of the parties under this Agreement, including, but not limited to, Sections 14 and 15, shall survive any termination of the Executive’s employment or termination or expiration of this Agreement to the extent necessary to the intended preservation of such rights and obligations.

17. No Mitigation or Set Off. In no event shall the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement and such amounts shall not be reduced, regardless of whether the Executive obtains other employment. During the pendency of any claim between the Company and Executive, the Company’s obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder with respect to any set-off, counterclaim, recoupment, defense or other right which the Company may have against the Executive or others, may be determined on an interlocutory basis by a competent court or arbitration tribunal.

18. Notices. All notices and other communications required or permitted under this Agreement or necessary or convenient in connection herewith shall be in writing and shall be deemed to have been given when hand delivered or mailed by registered or certified mail, as follows (provided that notice of change of address shall be deemed given only when received):

If to the Company, to:

Odyssey Health, Inc.

Las Vegas, NV

Attention: CEO

If to the Executive, to the most recent address on file with the Company or to such other names or addresses as the Company or the Executive, as the case may be, shall designate by notice to each other person entitled to receive notices in the manner specified in this Section.

19. Withholding. All payments under this Agreement shall be made subject to applicable tax withholding, and the Company shall withhold from any payments under this Agreement all federal, state and local taxes as the Company is required to withhold pursuant to any law or governmental rule or regulation.

20. Remedies Cumulative; No Waiver. No remedy conferred upon a party by this Agreement is intended to be exclusive of any other remedy, and each and every such remedy shall be cumulative and shall be in addition to any other remedy given under this Agreement or now or hereafter existing at law or in equity. No delay or omission by a party in exercising any right, remedy or power under this Agreement or existing at law or in equity shall be construed as a waiver thereof, and any such right, remedy or power may be exercised by such party from time-to-time and as often as may be deemed expedient or necessary by such party in its sole discretion.

21. Assignment. All of the terms and provisions of this Agreement shall be binding upon and inure to the benefit of and be enforceable by the respective heirs, executors, administrators, legal representatives, successors and assigns of the parties hereto, except that the duties and responsibilities of the Executive under this Agreement are of a personal nature and shall not be assignable or delegable in whole or in part by the Executive. Successors of the Company shall include, without limitation, any company or companies acquiring, directly or indirectly, all or substantially all of the assets of the Company, whether by merger, consolidation, purchase, lease, or otherwise, and such successor shall thereafter be deemed “the Company” for the purpose of this Section 21.

22. Entire Agreement.

(a) This Agreement, including all referenced addendums and exhibits, embodies the entire agreement of the parties with respect to its subject matter and merges with and supersedes all prior discussions, agreements, commitments, or understandings of every kind and nature relating to Executive’s employment, whether oral or written, between Executive and the Company. Neither party shall be bound by any term or condition other than as is expressly set forth in this Agreement.

(b) Executive represents and agrees that she fully understands her right to discuss all aspects of this Agreement with her private attorney, that to the extent she desired Executive availed himself of this right, that Executive has carefully read and fully understands all of the provisions of the Agreement, that Executive is competent to execute this Agreement, that her decision to execute this Agreement has not been obtained by any duress, that Executive freely and voluntarily enters into this Agreement, and that Executive has read this document in its entirety and fully understands the meaning, intent, and consequences of this Agreement.

23. Amendment. This Agreement may be changed, modified or amended only by a written document signed by the Executive and the Board.

24. Severability. If any provision of this Agreement or application thereof to anyone or under any circumstances is adjudicated to be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect any other provision or application of this Agreement which can be given effect without the invalid or unenforceable provision or application and shall not invalidate or render unenforceable such provision or application in any other jurisdiction. If any provision is held void, invalid or unenforceable with respect to particular circumstances, it shall nevertheless remain in full force and effect in all other circumstances.

25. Governing Law. This Agreement and any claims arising out of relating to this Agreement, whether in contract or tort, statutory or common law, shall be governed exclusively by, and construed in accordance with the laws of the State of Nevada without regard to principles of conflicts of laws.

26. Forum Selection and Consent to Jurisdiction. ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT, SHALL BE BROUGHT AND MAINTAINED EXCLUSIVELY IN THE COURTS OF THE STATE OF NEVADA OR IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEVADA; THE PARTIES HEREBY EXPRESSLY AND IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH THEY MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.

27. Waiver of Jury Trial. EACH PARTY HEREBY WAIVES ANY RIGHT TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING TO ENFORCE OR DEFEND ANY RIGHTS UNDER THIS AGREEMENT AND ANY AMENDMENT, INSTRUMENT, DOCUMENT OR AGREEMENT DELIVERED OR WHICH MAY IN THE FUTURE BE DELIVERED IN CONNECTION HEREWITH OR THEREWITH OR ARISING FROM ANY RELATIONSHIP EXISTING IN CONNECTION WITH ANY OF THE FOREGOING, AND AGREES THAT ANY SUCH ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY.

28. Service of Process: Each party hereto hereby consents to service of process in any action between any of the Parties hereto arising in whole or in part under or in connection with this Agreement, any document related to, or the negotiation, terms or performance hereof or thereof, (a) in any manner permitted by Nevada law or (b) by overnight delivery by a nationally recognized courier service at the respective address specified in this Agreement, and waives and agrees not to assert (by way of motion, as a defense or otherwise) in any such Action any claim that service of process made in accordance with clause (a) or (b) does not constitute good and valid service of process.

29. Counterparts; Electronic Transmission. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission (including an electronically-signed PDF) shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

Read and Agreed to:

Erik Emerson

/s/ Erik Emerson

Date: 11/1/2022

Odyssey Pharmaceuticals Inc.

By:

/s/ J. Michael Redmond

Date: 11/1/2022

EX-10.2 3 odyssey_ex1002.htm EMPLOYMENT AGREEMEN TBY AND BETWEEN ODYSSEY GROUP INTERNATIONAL, INC. AND GREG GIRONDA

Exhibit 10.2

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between Odyssey NeuroPharma, Inc., a wholly owned subsidiary of Odyssey Health, Inc., (the “Company”) a Nevada Corporation and Greg Gironda (the “Executive”) whose address is________________.

WHEREAS, the Company desires to employ the Executive as its Chief Operating Officer and the Executive desires to serve in such capacity on behalf of the Company.

WHEREAS, the Company and the Executive desire to enter into this Agreement to set forth the terms and conditions of the employment relationship between the Company and the Executive;

1. Employment.

2. Compensation.

125,000 vest upon signing of this agreement

300,000 vest upon a financing by the Company in the amount of $5,000,000 or more.

175,000 vest upon the listing of the Company on a national exchange such as Nasdaq or the NYSE.

(iii) The sale, lease, exchange or other transfer (in one transaction or a series of related transactions) of all or substantially all of the assets of the Company; or

(iv) The liquidation or dissolution of the Company or the Company ceasing to do business.

6. Termination .. The Company may terminate the Executive’s employment at any time. Executive may terminate Employment at any time. No severance will be paid to Executive upon termination.

13. Section 409A.

(j) The provisions of this Section 14 and Section 15 below shall survive any termination of the Executive’s employment or the termination or expiration of this Agreement for a period of six months.

15. Legal and Equitable Remedies.

If to the Company, to:

Odyssey Health, Inc.

Las Vegas, NV

Attention: CEO

22. Entire Agreement.

23. Amendment. This Agreement may be changed, modified or amended only by a written document signed by the Executive and the Board.

Read and Agreed to:

Gregory Gironda

/s/ Gregory Gironda

Date: 10/31/2022

Odyssey Pharmaceuticals Inc.

By:

/s/ J. Michael Redmond

Date: 11/1/2022

EX-99.1 4 odyssey_ex9901.htm PRESS RELEASE

Exhibit 99.1

Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team

Las Vegas, Nevada, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving medical products, is pleased to announce its continued commitment to the newly formed entity, Odyssey NeuroPharma, with the expansion of its executive team.

Joining the executive team at Odyssey NeuroPharma to advance Odyssey’s concussion treatment, and Niemann-Pick treatment, is Erik Emerson as Chief Commercial Officer and Greg Gironda as Chief Operating Officer. Mr. Emerson and Mr. Gironda have over 50 years of collective pharmaceutical experience in commercializing innovative pharmaceutical compounds with leading pharmaceutical companies.

“Odyssey NeuroPharma is dedicated to addressing the unmet medical needs in traumatic brain injury. Erik and Greg will provide the proven experience and expertise needed to bring this novel treatment through clinical trials and ultimately to commercial launch,” said Michael Redmond, CEO of Odyssey Health.

“The team at Odyssey is committed to bringing solutions to a devastating but poorly understood issue. The opportunity to impact the lives of our military, elderly, children, and athletes was something that one can only hope for in our careers.” Mr. Erik Emerson continued, “mild traumatic brain injury and the subsequent long-term effects are a true urgency. Joining the team at this critical juncture to lead our conversion of strong early science, to potential patient availability is unique.

Concussions effect all segments of our society, with over 5 million occurrences annually in the U.S. alone. Currently, there are no FDA approved treatments available. Odyssey Neuropharma is planning a Phase II program, which will evaluate efficacy in support of its extensive safety and animal data.

About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)

Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus in life-saving medical products and solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The Company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the Company’s website at www.odysseyhealthinc.com

We encourage our shareholders to visit our corporate social media accounts for updates:

https://twitter.com/OdysseyHealth1

https://www.facebook.com/odysseyhealthinc

https://www.linkedin.com/company/odysseyhealthinc

https://www.youtube.com/channel/UCsS--v0od_fYIBu2tvqmj9Q

About Odyssey NeuroPharma Inc.

Odyssey NeuroPharma, Inc., is a wholly-owned subsidiary of Odyssey Health Inc. and focused on developing drugs to treat neurological disorders. The blood-brain barrier (“BBB”) represents a significant obstacle for drug delivery to the brain. Many drugs have failed in neuroscience research due to the inability to jump the hurdle that is the BBB. The Odyssey NeuroPharma will use its unique intranasal delivery device coupled with its powdered formulations to let drugs be delivered more directly to the brain, providing for efficient and quick delivery. This targeted approach requires less drug to accomplish neuroprotection further reducing drug levels in the plasma which reduces side effects.

Forward-Looking Statements

This news release may have forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements because of various factors and uncertainties, including our ability to continue to raise needed funds, complete the Phase II trial, our ability to develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.

Inquiries:

Odyssey Health
info@odysseyhealthinc.com

EX-101.SCH 5 odyy-20221104.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 odyy-20221104_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 odyy-20221104_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Nov. 04, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 04, 2022
Entity File Number	000-56196
Entity Registrant Name	ODYSSEY HEALTH, INC.
Entity Central Index Key	0001626644
Entity Tax Identification Number	47-1022125
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	2300 West Sahara Avenue, Suite 800 - #4012
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89102
City Area Code	702
Local Phone Number	780-6559
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Trading Symbol	ODYY
Title of 12(g) Security	Common Stock ($0.001 par value)
Entity Emerging Growth Company	false

XML 9 odyssey_8k_htm.xml IDEA: XBRL DOCUMENT 0001626644 2022-11-04 2022-11-04 iso4217:USD shares iso4217:USD shares 0001626644 false 8-K 2022-11-04 ODYSSEY HEALTH, INC. NV 000-56196 47-1022125 2300 West Sahara Avenue, Suite 800 - #4012 Las Vegas NV 89102 702 780-6559 false false false false Common Stock ($0.001 par value) ODYY false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 21 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://theodysseygroupinternational.com/role/Cover Cover Cover 1 false false All Reports Book All Reports odyssey_8k.htm odyssey_ex1001.htm odyssey_ex1002.htm odyssey_ex9901.htm odyy-20221104.xsd odyy-20221104_lab.xml odyy-20221104_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "odyssey_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "odyssey_8k.htm" ] }, "labelLink": { "local": [ "odyy-20221104_lab.xml" ] }, "presentationLink": { "local": [ "odyy-20221104_pre.xml" ] }, "schema": { "local": [ "odyy-20221104.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 21, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ODYY", "nsuri": "http://theodysseygroupinternational.com/20221104", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "odyssey_8k.htm", "contextRef": "From2022-11-04to2022-11-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://theodysseygroupinternational.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "odyssey_8k.htm", "contextRef": "From2022-11-04to2022-11-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://theodysseygroupinternational.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0001683168-22-007279-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-22-007279-xbrl.zip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end